Monograph
C02CA04 - Doxazosin |
Propably not porphyrinogenic |
PNP |
Rationale
No data pointing to CYP-interaction. Clinical experience of non-porphyrinogenicity.
Chemical description
Quinazoline derivative
Therapeutic characteristics
Antihypertensive quinazoline derivative, also used in prostatic hyperplasia. Dose 4-8 mg/d.
Metabolism and pharmacokinetics
Extensively metabolised in the liver, primarily excreted in faeces as metabolites and only a small amount of unchanged drug. Oxidative metabolism occurs, but data on CYP450 metabolism are lacking.
Personal communication
Thunell, patient reports (n=5): tolerated. Andersson, patient reports(n=11): tolerated.
Published experience
Doxazosin was used uneventfully in 60 year old AIP woman (Gorchein, 1997). Also used uneventfully in AIP man of 55 (Turton-Weeks, 2001).
IPNet drug reports
Uneventful use reported in 19 patients with acute porphyria.
References
| # |
Citation details |
PMID |
|---|
| * | Scientific articles |
| 1. |
Drug treatment of hypertension in acute intermittent porphyria: Doxazosin and amlodipine. British Journal of Clinical Pharmacology 1997; 43(3):339-340.
Gorchein A. |
9088595 |
| 2. |
Pretransplant evaluation of a patient with acute intermittent porphyria. Progress in Transplantation 2001; 11(3):214-216.
Turton-Weeks S, Barone GW, et al. |
11949465 |
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
United Kingdom
Denmark
Norway
Poland
Iceland
Latvia
Serbia
